日本唑来膦酸一年一次注射治疗骨质疏松症的成本效果分析
该研究采用患者水平状态转换模型,评估日本一年一次注射唑来膦酸治疗骨质疏松症的成本效果。在考虑治疗持续性的情景分析中,与阿仑膦酸钠相比,唑来膦酸的增量成本效果比(ICER)在T值-2.0、-2.5、-3.0患者中分别为47,435、27,018、10,749美元/QALY。作者认为,尽管唑来膦酸被阿仑膦酸钠支配,但增量QALY很小,考虑其一年一次注射在依从性和持续性上的优势,可能具有成本效果。
要点
- 模型显示唑来膦酸被阿仑膦酸钠支配,增量QALY为-0.004至-0.000,增量成本430至493美元。
- 考虑治疗持续性后,唑来膦酸对比阿仑膦酸钠的ICER在T值-2.0、-2.5、-3.0患者中分别为47,435、27,018、10,749美元/QALY。
- 作者认为,考虑一年一次唑来膦酸在依从性和持续性上的优势,其可能为具有成本效果的治疗选择。
核心结论
- 尽管唑来膦酸被阿仑膦酸钠支配,但增量QALY幅度很小;考虑一年一次唑来膦酸治疗在依从性和持续性上的优势,与阿仑膦酸钠相比,唑来膦酸可能是一种具有成本效果的治疗选择。
研究设计与样本
- 基于模型的经济学评价,开发患者水平状态转换模型,预测曾发生椎体骨折的骨质疏松症患者的结局。
- 唑来膦酸疗效来自已发表的网状Meta分析,估计终生成本和QALY,比较唑来膦酸、阿仑膦酸钠或单纯基础治疗。
主要发现
- 对于70岁患者,唑来膦酸被阿仑膦酸钠支配,增量QALY为-0.004至-0.000,增量成本为430美元至493美元。
- 确定性敏感性分析表明,髋部骨折的相对风险和药物成本强烈影响唑来膦酸相对于阿仑膦酸钠的成本效果。
- 考虑治疗持续性的情景分析显示,唑来膦酸对比阿仑膦酸钠的ICER在T值-2.0、-2.5、-3.0患者中分别为47,435美元、27,018美元、10,749美元/QALY。
关键数值与推荐
- 唑来膦酸对比阿仑膦酸钠的ICER:T值-2.0患者为47,435美元/QALY,T值-2.5患者为27,018美元/QALY,T值-3.0患者为10,749美元/QALY。
- 70岁患者中,唑来膦酸对比阿仑膦酸钠的增量QALY为-0.004至-0.000,增量成本为430美元至493美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Model-based economic evaluation was performed to assess the cost-effectiveness of zoledronic acid. Although zoledronic acid was dominated by alendronate, the incremental quality-adjusted life year (QALY) was quite small in extent. Considering the advantage of once-yearly injection of zoledronic acid in persistence, zoledronic acid might be a cost-effective treatment option compared to once-weekly oral alendronate. INTRODUCTION: The purpose of this study was to estimate the cost-effectiveness of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. METHODS: A patient-level state-transition model was developed to predict the outcome of patients with osteoporosis who have experienced a previous vertebral fracture. The efficacy of zoledronic acid was derived from a published network meta-analysis. Lifetime cost and QALYs were estimated for patients who had received zoledronic acid, alendronate, or basic treatment alone. The incremental cost-effectiveness ratio (ICER) of zoledronic acid was estimated. RESULTS: For patients 70 years of age, zoledronic acid was dominated by alendronate with incremental QALY of -0.004 to -0.000 and incremental cost of 430 USD to 493 USD. Deterministic sensitivity analysis indicated that the relative risk of hip fracture and drug cost strongly affected the cost-effectiveness of zoledronic acid compared to alendronate. Scenario analysis considering treatment persistence showed that the ICER of zoledronic acid compared to alendronate was estimated to be 47,435 USD, 27,018 USD, and 10,749 USD per QALY gained for patients with a T-score of -2.0, -2.5, or -3.0, respectively. CONCLUSION: Although zoledronic acid is dominated by alendronate, the incremental QALY is quite small in extent. Considering the advantage of annual zoledronic acid treatment in compliance and persistence, zoledronic acid may be a cost-effective treatment option compared to alendronate.
引用
- Moriwaki K, Mouri M, Hagino H, et al. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int. 2017. PMID: 28265718. doi:10.1007/s00198-017-3973-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。